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Background: The Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis syndrome (PFAPA) is the
most common periodic fever syndrome in childhood. Clinically, PFAPA may resemble autoinflammatory diseases,
but the etiology is not fully understood.
Methods: We measured inflammatory proteins in plasma and hematologic parameters in children with PFAPA during
and between febrile episodes, and in a control group with suspected bacterial pneumonia. In children with PFAPA, a
first blood sample was taken within 24 hours of a febrile episode and a second sample between episodes. In children
with pneumonia, the first sample was taken shortly after admission and a second sample after full recovery.
Results: A total of 22 children with PFAPA and 14 children with pneumonia were included. In children with PFAPA,
levels of interleukin (IL) 6, CXCL10 and CCL4 were significantly increased during febrile episodes. The levels of IL-6 and
CXCL10 were higher in children with PFAPA during febrile episodes than in children with pneumonia. The levels of
CXCL10 remained higher in children with PFAPA between febrile episodes compared to children with pneumonia after
recovery. Children with PFAPA had a relative eosinopenia and lymphocytopenia with reduced numbers of both CD4+
and CD8+ T cells during febrile episodes. This pattern was not observed in the children with pneumonia.
Conclusions: The results indicate an innate immune response as the initial step in PFAPA, and a subsequent adaptive
response with activation and redistribution of T cells. Moreover, an activation of the innate immune system involving
CXCL10 may persist between febrile episodes. CXCL10 may be a possibly clinical marker in children with PFAPA.
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The syndrome of Periodic Fever, Aphthous stomatitis, Pha-
ryngitis and cervical. Adenitis (PFAPA) was first described
as a clinical entity by Marshall et al. in 1987 [1]. PFAPA is
an inflammatory disorder mainly of early childhood, with
periodic fever accompanied by a predictable set of symp-
toms with aphthous stomatitis, pharyngitis and cervical ad-
enitis being the most frequent. The most commonly used* Correspondence: fojo@sus.no
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reproduction in any medium, provided the orclinical diagnostic criteria were suggested by Thomas et al.
in 1999 [2]. PFAPA has been reported from different ethnic
groups [3], and recently we reported a yearly incidence of
2.3 per 10.000 children under the age of five in Norwegian
children [4].
The lack of a microbiological agent as the cause of fever
[1,2], a well-documented abrupt response to a single dose of
cortisone [5,6] and no evidence of autoimmunity have led to
the hypothesis that PFAPA is an autoinflammatory disease
[7-10]. For some of the autoinflammatory diseases the gen-
etic and pathophysiological mechanisms have been revealed,
but for PFAPA and others this remains unclear [7].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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four studies through different approaches [8-11]. In all
four studies cytokines were measured in serum, but with
different panels and different time-relation to the fever ep-
isodes. Except for a clear increase of serum interleukin
(IL) -6 during the febrile phase of PFAPA, no uniform re-
sults have been found. In two studies however, an increase
of the chemokines CXCL9 and CXCL10 during the febrile
phase was also reported [8,9]. In two studies IL-1β has
been suggested to play a pivotal role in PFAPA [9,10].
During the febrile phase of PFAPA, the immunological
response may mimic that of bacterial infections with high
levels of C-reactive protein (CRP) [12,13]. With the excep-
tion of one study which included children with hereditary
periodic fever syndromes during febrile attacks as controls
[9], only control groups of healthy children were included
in the studies of the etiology of PFAPA [8,10,11]. This may
limit the ability to study the PFAPA-specific immunological
characteristics during inflammation.
Our aim was to study the immunological and haemato-
logical characteristics in PFAPA during febrile episodes
and recovery, and include a control group with a well-
defined bacterial infection.
Methods
Study population
Since 2004, children with PFAPA diagnosed at Stavanger
University Hospital have been included in a prospective
study [4], and children included between 1st of January
2008 and 31st of August 2011 were invited to participate
in the present immunological study.
The diagnosis of PFAPA was set according to the criteria
suggested by Thomas et al. [2] as described in detail else-
where [4]. The children should not be suspected for or di-
agnosed with any other autoinflammatory or other disease
as the reason for recurrent fever. Cyclic neutropenia was
excluded in all patients by serial measurements of neutro-
phils two times weekly between two subsequent attacks.
During the febrile attacks the children were evaluated by
one of the authors (JF or KØ). A throat culture was col-
lected from all children during attacks; these were negative
in all children except for one child who was excluded from
the study. Children admitted to Stavanger University Hos-
pital with clinical symptoms of pneumonia, radiological
verified consolidation and CRP ≥ 150 mg/L and with no
chronic condition making theme prone to infections were
recruited as controls.
The study was approved by the regional committee of
research ethics, and an informed consent was obtained
from parents of all children.
Laboratory analyses
In children with PFAPA, a blood sample was taken within
24 hours of the onset of a typical febrile episode (PFAPA-f ) and another (non-febrile) blood sample was taken sub-
sequently between two febrile episodes (PFAPA-nf), after
at least 10 days without fever. If only one of two samples
was taken, the child was also included.
In children with pneumonia (Pn), blood samples were
taken as soon as possible after the diagnosis was set after
admission (Pn-f ). In most patients, a second blood sam-
ple was taken after complete resolution of their infec-
tion, at least four weeks after full recovery (Pn-nf ).
Systemic steroids were not given to children with PFAPA
or pneumonia during the study period. Non-steroid anti-
inflammatory drugs were only administrated after the blood
samples had been taken, except for one child with pneumo-
nia who had received one dose of ibuprofen 34 hours prior
to admission.
White blood cell count with subgroups of neutrophils,
monocytes, lymphocytes and eosinophils and thrombocytes
were analysed on a Sysmex XE-5000 (Kobe, Japan) as a part
of routine work-up.
Lymphocyte subpopulation quantifications were per-
formed using the BD Multitest 6-color TBNK kit with BD
Trucount Tubes for relative and absolute concentration de-
termination (BD Biosciences, San Jose, CA, USA). The
samples were prepared according to the manufacturer’s in-
structions and analyzed on a BD Canto II flow cytometer
(BD Biosciences) using BD Canto 2.1 analysis software.
In order to avoid ex vivo release or production of cyto-
kines after sampling, a citrate-coated collection tube was
immediately cooled and centrifuged by the use of a
Kubota 5930 centrifuge at 3300 rpm for eight minutes at
4°C. After centrifugation, the citrate plasma was pipetted
off and frozen at −80°C. Samples were thawed and divided
when analysed for cytokines. The part of the samples not
used for cytokine analysis was refrozen and stored.
Cytokines in serum were analysed using a 27-plex cyto-
kine panel (BioRad, CA, USA) and a Luminex-based
reader (Luminex Corporation, Texas, USA). Samples and
standards were prepared and analysed according to the
manufacturer’s instructions. The analyses were performed
in duplex. Manufacturer derived detection limit ranged
from 0.2-14.6 pg/ml depending on the cytokine (See
Table 1 for list of cytokines with the corresponding level
of detection). When available, the IUPHAR-nomenclature
was used for cytokines and chemokines [14].
Due to observed fluctuations in the subsets of
leucocytes and cytokine pattern, samples were later
analysed for soluble IL-2 receptor alpha (sCD25) and
sCD163 collectively.
sCD25 was analysed using a Quantikine Elisa Human
Soluble IL-2 receptor alpha Immunoassay (R&D Systems,
Minneapolis, USA). Samples and standards were prepared
and analysed according to the manufacturer’s instructions.
The minimal detectable dose is typically less than 10 pg/
ml according to the manufacturer.
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CD163 Immunoassay (R&D Systems). Samples and
standards were prepared and analysed according to the
manufacturer’s instructions. Sensitivity as stated by the
manufacturer: Forty-six assays were evaluated and the
minimum detectable dose of CD163 ranged from 0.058-
0.613 ng/ml. sCD25 and sCD163 samples were analysed
singly.
Serum immunoglobulin G (IgG), IgA, and IgM were
measured using a Siemens BN ProSpec Nephelometer.
Serum IgD was measured by radial immunodiffusion, (IgD
RID kit – NL, Binding Site, Birmingham, UK).
Statistical analyses
Values below standard range were accepted as they were,
but if the median value was below the level of detection
the results were referred to as not detectable. Values out
of range were set as the lowest and highest values detected
by the kit respectively.
Comparisons between groups were analysed by the chi-
square test and non-parametric Mann–Whitney U test.
When comparing samples from febrile and non-febrile
children within groups, only children with paired samples
were included and the results were analyzed with the
Wilcoxon Signed Ranks Test. P-values of <0.05 were
regarded as statistically significant. All statistical analyses
were performed using the IBM-SPSS version 20 statistical
package.
Results
Twenty-two children diagnosed with PFAPA were in-
cluded in the study. In 13 of these, blood samples were
collected both during (PFAPA-f) an in between (PFAPA-
nf) febrile episodes. In eight children, samples were taken
only during the non-febrile phase, and in one patient a
sample was taken only during the febrile phase.
Fourteen children with pneumonia were included. In
10 of these, samples were taken both during the febrile
(Pn-f ) phase and after full recovery (Pn-nf ). In four chil-
dren, a sample was taken only during the febrile phase
(Pn-f ). The characteristics of the children with PFAPA
and pneumonia are given in Table 2.
Leucocyte counts
Levels of leucocytes are presented in Table 3, and the
distribution of lymphocytes in Figure 1. The white blood
cell count, neutrophil count and monocyte count were
significantly higher and the lymphocyte and eosinophil
count was significantly lower in PFAPA-f compared to
PFAPA-nf. No significant differences were observed for
thrombocytes. The lymphocyte and eosinophil count in
PFAPA-f was significantly lower than in Pn-f, but no sig-
nificant difference was observed between non-febrilesamples (PFAPA-nf and Pn-nf ). The lymphocyte and eo-
sinophil count did not differ between Pn-f and Pn-nf.
Flow cytometric immunophenotyping of lymphocytes
Subsets of lymphocytes are presented in Table 3. The level
of CD4+ and CD8+ T-lymphocytes were significantly
lower in PFAPA-f compared to PFAPA-nf, and signifi-
cantly lower in PFAPA-f compared to Pn-f. The levels of
all subsets measured by immunophenotyping were similar
in PFAPA-nf and Pn-nf. No differences were observed be-
tween any of the groups for CD19+ and CD56+ positive
lymphocytes.
Cytokines
Levels of cytokines in plasma are presented in Table 1
and Figure 1. Levels of CXCL10, CCL4 and IL-6 were
higher in PFAPA-f than in PFAPA-nf. Levels of IL-1β
were low but detectable in children with PFAPA, but un-
detectable in children with pneumonia. The levels of IL-
1β and the other 23 cytokines did not differ between
PFAPA-f and PFAPA-nf.
Levels of IL-1β, CXCL10, IL-6, G-CSF and CCL2 were
significantly higher in PFAPA-f compared to Pn-f. CXCL10
was significantly higher in PFAPA-nf compared to Pn-nf.
CCL5, IL-2 and PDGF-BB were significantly lower in
PFAPA-nf than in Pn-nf.
IL-17, CCL5, IL-1ra, IL-2, IL-9, CCL11, FGF-2, CCL3 and
PDGF-BB were significantly lower in PFAPA-f than in Pn-f.
For the other cytokines no significant differences were
found between the groups.
sCD25 and sCD163
The measured levels of sCD25 were significantly higher
in PFAPA-f compared to PFAPA-nf.
There were no significant differences between PFAPA-f
and Pn-f or between PFAPA-nf and Pn-nf. Soluble CD163
did not differ between any of the groups (Table 4).
Immunoglobulins
For children with PFAPA, levels of IgG, IgM, and IgA
were within normal levels and did not differ from children
with pneumonia, and levels of immunoglobulin D were
within the age specific normal range for all children [15].
For children with PFAPA, the median value of IgD was
13.0 mg/L (quartiles: 12.9, 39.2).
Discussion
In this study we found increased levels of the pro-
inflammatory cytokines CXCL10, CCL4 and IL-6 dur-
ing febrile episodes in children with PFAPA compared
to non-febrile periods. These cytokines have in common
that they are produced in abundant amounts by cells of
the innate immune system. Although the cellular origin of
a cytokine measured in peripheral blood is unknown, most
Table 1 Levels of cytokines in children with the periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis
syndrome (PFAPA) and children with pneumonia (Pn)
Pn-nf p-value PFAPA-nf p-value PFAPA-f p-value Pn-f
Pn-nf PFAPA-f PFAPA-f
vs vs vs
PFAPA-nf PFAPA-nf Pn-f
(n=10) (n=21) (n=13) (n=14) (n=14)
IL-1β nd 0.004 2.5 ns 2.6 0.002 nd
(LoD: 0.8) (0.1, 5.4) (0.9, 5.1)
CXCL10 731.9 0.000 1762.5 .003 4787.2 0.002 1512.7
(LoD: 6.5) (582.7, 1038.0) (1305.6, 3401.0) (2801.1, 7743.5) (685.5, 3179.4)
IL-6 15.4 ns 11.2 .001 49.6 0.035 21.7
(LoD: 1.1) (9.5, 23.7 (4.8, 19.0) (21.1, 103.8) (18.3, 29.7)
CCL4 70.5 ns 52.8 .019 63.0 ns 59.4
(LoD: 1.1) (52.9, 83.6) (30.3, 77.2) (47.5, 93.4) (44.7, 75.0)
IL-17 41.6 ns 17.4 ns 7.4 0.002 64.5
(LoD: 0.2) (25.4, 135.7) (0.7, 54.6) (0.7, 29.5) (26.6, 81.2)
CCL5 6878.3 0.017 3197.5 ns 3007.8 0.016 4856.7
(LoD: 1.2) (4066.2, 7154.3) (2200.8, 4694.1) (1864.5, 4019.3) (3028.0, 6916.8)
IL-1ra 234.0 ns 129.3 ns 121.5 0.002 249.3
(LoD: 1.4) (116.4, 368.1) (69.5, 196.8) (95.7, 170.8) (176.7, 328.9)
IL-2 17.6 0.010 nd ns nd 0.000 17.6
(LoD: 1.1) (7.3, 29.9) (9.2, 21.7)
IL-9 24.4 ns 4.0 ns 6.0 0.011 29.7
(LoD: 0.7) (11.6, 77.5) (0.6, 30.8) (0.5, 17.7) (15.3, 41.3)
CCL11 65.0 ns 20.8 ns nd 0.007 59.3
(LoD: 14.6) (10.4, 133.1) (0.3, 71.6) (14.7, 115.1)
FGF-2 35.9 ns 24.0 ns 26.4 0.044 44.7
(LoD: 6.8) (24.5, 63.2) (4.8, 47.7) (14.1, 40.6) (27.4, 55.7)
G-CSF 74.0 ns 92.0 ns 126.9 0.016 94.0
(LoD: 1.1) (54.8, 103.4) (61.6, 111.9) (95.9, 169.0) (55.6, 106.9)
CCL2 38.0 ns 36.1 ns 38.0 0.039 27.6
(LoD: 6.8) (34.5, 41.9) (26.2, 42.1) (28.4, 54.5) (19.2, 32.9)
CCL3 15.5 ns 3.0 ns 4.2 0.004 16.9
(LoD: 2.4) (8.2, 21.5) (0.2, 14.8) (0.4, 7.0) (13.6, 18.9)
PDGF-BB 1440.5 0.025 532.4 ns 406.0 0.004 1284.0
(LoD: 1.0) (529.7, 1942.0) (301.5, 910.1) (263.2, 1093.6) (1056.0, 2813.3)
CXCL8 (IL-8) 19.1 ns 20.1 ns 19.0 ns 24.3
(LoD: 0.5) (12.7, 32.3) (14.0, 29.9) (15.6, 23.4) (18.5, 29.1)
INF-γ 198.9 ns 279.4 ns 323.5 ns 226.6
(LoD: 19.3) (125.3, 336.9) (208.3, 418.9) (235.3, 437.4) (166.7, 306.3)
IL-4 5.7 ns 7.0 ns 6.8 ns 6.8
(LoD: 0.5) (3.1, 8.2) (4.9, 9.8) (4.9, 9.4) (4.4, 8.2)
IL-5 6.3 ns 5.7 ns 5.8 ns 12.0
(LoD: 0.8) (1.8, 21.2) (3.1, 9.4) (4.5, 9.3) (1.8, 18.3)
IL-7 19.9 ns 25.9 ns 25.4 ns 19.5
(LoD: 0.5) (11.5, 26.3) (19.1, 31.1) (19.4, 29.6) (12.5, 26.3)
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Table 1 Levels of cytokines in children with the periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis
syndrome (PFAPA) and children with pneumonia (Pn) (Continued)
IL-10 13.1 ns 6.5 ns 8.1 ns 8.3
(LoD: 0.9) (1.6, 24.9) (3.2, 13.7) (4.3, 11.1) (1.2, 16.8)
IL-12p70 46.1 ns 25.8 ns 24.5 ns 40.4
(LoD: 0.5) (18.5, 89.5) (12.2, 40.8) (18.1, 33.4) (14.2, 72.2)
IL-13 16.9 ns 10.1 ns 10.4 ns 13.3
(LoD: 2.1) (8.3, 36.1) (6.4, 17.5) (7.6, 14.0) (7.2, 21.9)
IL-15 nd ns nd ns nd ns nd
(LoD: 4.2)
GM-CSF nd ns nd ns nd ns nd
(LoD: 4.5)
TNF-α 66.2 ns 67.1 ns 68.1 ns 82.5
(LoD: 3.0) (40.6, 126.8) (42.9, 101.6) (56.3, 113.1) (55.9, 116.2)
VEGF 43.2 ns 22.3 ns 30.6 ns 38.3
(LoD: 0.5) (24.4, 70.0) (9.2, 47.1) (9.1, 43.4) (21.7, 87.3)
Values are given as pg/ml and presented as median (quartiles).
Pn-nf: Children with pneumonia after complete remission.
PFAPA-nf: Children with PFAPA between febrile episodes.
PFAPA-f: Children with PFAPA during febrile episodes.
Pn-f: Children with pneumonia shortly after admission.
LoD: Limit of detection as stated by the manufacturer.
ns: not significant.
nd: not detectable.
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observed pattern of cytokines in this study substantiate an
innate trigger in PFAPA. The levels of CXCL10 were
higher in PFAPA even between febrile episodes, suggesting
a persistent activation of the immune system.
The lymphocyte and eosinophil count in blood decreased
and the numbers of both CD4+ and CD8+ T cells were
lower during febrile episodes. The observed fluctuations in
T cells indicate an adaptive activation and recruitment of
these cells to secondary lymphoid organs. CXCL10 and
CCL4 are chemo-attractants and may act as link between
an innate and an adaptive immune response in PFAPA.
CXCL10 is a small chemokine (a chemotactic cytokine)
formerly denoted interferon-γ induced protein 10. CXCL10
is one of three known ligands for the CXCR3 chemokine-
receptor [16]. Under the influence of interferon-γ, manyTable 2 Clinical characteristics of children with the periodic fe
adenitis syndrome (PFAPA) and children with pneumonia
PFAPA (n =
Gender (boys / girls) 14 / 8
Age at time of sampling (months) † 36.5 (23.8, 62
Duration of fever at time of sampling (hours) 14.0 (11.5, 16
Age of onset (months) 9.5 (4.3, 12.0
Duration of febrile episodes (days) 3.8 (3.0, 5.0)
Results are given as median (quartiles) except for gender.
†Age at first sample in all children.
‡n = 14.different cell-types like monocytes, neutrophils, astrocytes,
endothelial cells, keratinocytes and fibroblasts can produce
CXCL10, but seemingly CXCL10 can also be induced dir-
ectly by early innate mechanisms [17,18]. CXCL10 is a
powerful chemo-attractant for both CD4+ and CD8+ T
cells to the site of inflammation, and is expressed in vari-
ous Th1 type inflammatory diseases [17], and has also
been implicated in autoimmune disease [19].
CCL4 was formerly denoted macrophage inflammatory
protein 1β and is also a chemokine with pro-inflammatory
effects [20]. As CXCL10, CCL4 is a chemo-attractant for
T cells. CCL4 is produced as a result of an early innate
stimulus by activated macrophages and also by a variety of
other activated immune cells [18,20].
IL-6 is an important pro-inflammatory cytokine and has
many different cellular targets. Macrophages, dendritic cellsver, aphthous stomatitis, pharyngitis and cervical
22) Pneumonia (n = 14) p-values
7 / 7 0.418
.6) 34.1 (17.5, 51.1) 0.860
.5)‡ 96.0 (60.0, 135) <0.001
)
Table 3 Haematological variables and lymphocyte populations in children with the periodic fever, aphthous stomatitis,
pharyngitis and cervical adenitis syndrome (PFAPA) and children with pneumonia (Pn)
Pn-nf p-value PFAPA-nf p-value PFAPA-f p-value Pn-f
Pn-nf PFAPA-nf PFAPA-f
vs vs vs
PFAPA-nf PFAPA-f Pn-f
(n=10) (n= 21) (n=13) (n=14) (n=14/12*)
White blood cells (109/L) 9.2 ns 7.9 0.003 13.3 ns 14.7
(6.1, 11.4) (5.7, 10.1) (9.4, 15.2) (10.5, 19.2)
Neutrophils (109/L) 3.15 ns 3.2 0.002 9.2 ns 9.1
(2.3, 5.6) (2.5,4.1) (5.8, 11.8) (5.0, 14.7)
Thrombocytes (109/L) 366 ns 355 ns 299 ns 385
(289, 413) (296, 427) (269, 353) (275, 482)
Lymphocytes (109/L) 3.95 ns 3.0 0.004 2.3 0.006 3.8
(2.5, 4.8) (2.4, 4.4) (1.5,3.1) (2.5, 4.6)
Monocytes (109/L) 0.7 ns 0.6 0.002 1.4 ns 1.3
(0.5, 0.8) (0.6, 0.8) (1.2, 1.8) (1.1, 1.6)
Eosinophils (109/L) 0.2 ns 0.2 0.002 0.0 0.009 0.2
(0.1, 0.5) (0.1, 0.4) (0.0, 0.1) (0.03, 0.3)
(n=9) (n=15) (n=8) (n=8) (n=10)
CD3 (106/L) 2583 ns 2527 0.012 1087 0.021 2145
(1744, 3098) (1998, 3006) (894, 1592) (1211, 3368)
CD4 (106/L) 1294 ns 1478 0.017 698 0.041 1310
(1034, 1619) (1025, 1909) (494, 1062) (765, 2006)
CD8 (106/L) 1196 ns 891 0.012 359 0.010 801
(655, 1325) (658, 1022) (254, 420) (399, 1084)
CD56 (106/L) 253 ns 414 ns 203 ns 172
(193, 354) (224, 590) (116, 329) (62.5, 303)
CD19 (106/L) 629 ns 596 ns 574 ns 991
(403, 880) (430, 1247) (346, 823) (393, 1109)
Results are given as median (quartiles).
Pn-nf: Children with pneumonia after complete remission.
PFAPA-nf: Children with PFAPA between febrile episodes.
PFAPA-f: Children with PFAPA during febrile episodes.
Pn-f: Children with pneumonia shortly after admission.
ns: not significant.
* Lymphocytes, monocytes and eosinophils were measured in 12 children with Pn-f.
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the abundant IL-6 release observed in PFAPA also indicates
trigging of the innate immune system [21]. Like IL-1β, IL-6
induces the production of acute phase proteins, pyrexia and
sickness behaviour [21,22]. The increased levels of CRP and
serum amoyloid A, high fever and malaise following febrile
attacks of PFAPA [4,8,9,12] may be attributed to the increase
of IL-6.
The elevation of CXCL10 and IL-6 during febrile epi-
sodes of PFAPA has been showed in three previous studies
[8-10] and elevated CCL4 in one study [9]. An immune re-
sponse can be characterised on the basis of the cytokinesproduced by helper T cells after activation. IL-2 and INF-γ
are signature cytokines of a Th1 like immune response [23].
The elevation of CXCL10 in the absence of increased Th2-
and Th17 cytokines has been used as an argument for a
Th1 like immune response in PFAPA [8-10]. This study re-
ports a similar pattern, but also as in previous studies [8,9]
we did not find an increase in Th1 signature cytokines such
as INF-γ or IL-2 during the febrile attacks of PFAPA. How-
ever, the increase in CXCL10 may suggest a mechanism for
activation and recruitment of T-lymphocytes to local tis-
sues, as suggested by the alterations in CD4+ and CD8+
lymphocytes.
Figure 1 Levels of CXCL10, Interleukin (IL) 6, CCL4 and number of lymphocytes in children with PFAPA during (f) and outside febrile
episodes (nf), and in children with pneumonia (Pn) during the episode (f) and after recovery (nf). The line represents the median value.
CXCL10 and IL-6 are presented with a log scale.
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in PFAPA to some extent persists between flares. Brown
found thrombocytosis in the afebrile interval, whereas
Stojanov et al. in 2006 reported higher levels of serum IL-
1β, IL-6, TNF-α and IL-12p70 in the afebrile interval of
PFAPA compared to healthy controls [8,11]. In 2011,
Stojanov et al. reported higher levels of CXCL9, CCL4, IL-6
and G-CSF in the afebrile interval of PFAPA compared toTable 4 Levels of soluble IL-2 receptor alpha (sCD25) and sCD
stomatitis, pharyngitis and cervical adenitis syndrome (PFAP
Pn-nf PFAPA
(n=10) (n=20
sCD25 (pg/ml) 1162.3 1883.
(820.4, 2110.3) (970.4, 24
sCD163 (ng/ml) 568.8 665.8
(408.5, 735.0) (555.7, 8
Results are given as median (quartiles).
Pn-nf: Children with pneumonia after complete remission.
PFAPA-nf: Children with PFAPA between febrile episodes.
PFAPA-f: Children with PFAPA during febrile episodes.
Pn-f: Children with pneumonia shortly after admission.
For sCD25 measurements the p-value was 0.013 for PFAPA-f versus PFAPA-nf, and t
No other significant differences were found for sCD25 or sCD163.
* sCD163 was measured in 13 children with PFAPA and in 12 children with pneumocontrols [9]. We could not confirm these results. However,
a novel finding in our study is that levels of CXCL10 were
higher in children with PFAPA than in the control group
also outside the febrile episode. Interestingly, Stojanov et al.
also reported higher levels of CXCL10 and G-CSF during
febrile attacks of PFAPA than during febrile attacks of other
defined hereditary fever syndromes [9]. Together, these re-
sults may indicate that pathways involving CXCL10 play163 in children with the periodic fever, aphthous
A) and children with pneumonia (Pn)
-nf PFAPA-f Pn-f
) (n=14/13*) (n=14/12*)
4 2980.2 2297.6
58.5) (1032.4, 3624.4) (1799.2, 3381.3)
695.4 505.3
44.4) (528.0, 813.0) (391.3, 837.1)
he p-value was 0.022 for Pn-f versus Pn-nf.
nia.
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this process may be active also between the febrile epi-
sodes. This could possibly have a genetic background.
Finally, CXCL10 may be further studied as a possibly
clinical marker in children with PFAPA.
Differences in cytokine patterns between children with
PFAPA and controls have also been found between flares.
Stojanov et al. found lower levels of IL-4 at all times in chil-
dren with PFAPA compared to controls, which may be con-
sistent with the recent finding that IL-4 cytokine gene
expression in the tonsils and peripheral blood eosinophils
were lower in PFAPA patients compared to controls [11,24].
These results could suggest an ongoing suppression of Th2
responses. We found that levels of CCL5, IL-2 and PDGF
were lower in PFAPA-nf than in Pn-nf, and these cytokines
were also decreased in children with PFAPA during fever.
The relevance of this is, however, not known.
In this study the observed levels of IL-1β in the children
with PFAPA were low but elevated in comparison to chil-
dren with pneumonia. In 2011, Stojanov et al. concluded
that PFAPA is a disorder of innate immunity and demon-
strated a prompt response to a recombinant IL-1 receptor
antagonist in five children with PFAPA [9]. Kolly et al.
found increased release of IL-1β from stimulated peripheral
blood mononuclear cells and stimulated monocytes in chil-
dren with PFAPA during febrile episodes [10]. Stojanov
et al. and Kolly et al. conclude that IL-1β is likely to have a
pivotal role in PFAPA, but they did not find elevated levels
of serum IL-1β in the children’s blood samples [9,10]. Our
result may to some extent support their theory, but the re-
sults are inconclusive.
The haematological pattern, with an increase of total
number of white blood cells, neutrophils and monocytes
and a decrease of lymphocytes and eosinophils in children
during febrile PFAPA episodes, has also been described by
others [8,9]. Stojanov et al. found that this pattern differed
from children with flares of hereditary periodic fever syn-
dromes, whereas Brown et al. did not include a febrile con-
trol group [8,9]. In our study, the lymphocyte counts were
lower during febrile episodes in children with PFAPA, but
not in children with pneumonia. In children with severe
H1N1 pneumonia, serum levels of CXCL10 and IL-6 has
been found to be negatively associated with lymphocyte
count and disease severity, supporting the role of CXCL10
in recruiting lymphocytes to local tissues [25]. This was not
seen in children with community acquired pneumonia. The
difference between the two groups in our study may, how-
ever, also have been influenced by the different timing of the
analyzes.
During severe infections, eosinopenia may be seen as a
normal response associated with a Th1 type of inflam-
mation, whereas the absence of eosinopenia has been as-
sociated with a Th2 driven response [26,27]. The relative
eosinopenia observed by us and others during episodesof PFAPA could therefore be an indication that the in-
flammation during PFAPA is mainly Th1 driven.
The relative lymphocytopenia corresponds with the de-
crease in CD4+ and CD8+ subsets of T-lymphocytes, as
also described by Stojanov et al. [9]. This is consistent with
an activation and redirection of T cells from the blood-
stream to local tissue such as lymph nodes and possibly
tonsils during febrile episodes in PFAPA. Clinically, this
may be seen as the tender cervical adenitis and pharyngitis
which are common clinical features of PFAPA [1,2,4-6].
Three studies have reported the results of histological
evaluation of tonsils removed from children with PFAPA.
They all report signs of chronic inflammation with lymph-
oid hyperplasia [28-30].
Due to the observed decrease of CD4+ and CD8+ cells in
peripheral blood during the febrile episodes of PFAPA, we
measured sCD25 in serum. sCD25 is an indicator of T cell
activation, and elevated levels have been described in a var-
iety of cancerous and non-cancerous conditions [31-33].
The significant increase of sCD25 observed during the fe-
brile attacks of PFAPA indicates that T cell activation is
present, supporting the other results. However, a similar in-
crease during the acute phase of an infection was found in
the children with pneumonia.
CD163 is a scavenger receptor involved in the endo-
cytosis of haptoglobin-haemoglobin complexes and is
expressed on macrophages and on a fraction of mono-
cytes [34]. Elevated sCD163 has been described in dif-
ferent conditions including hemophagocytic syndrome,
sepsis and rheumatoid arthritis [34-36]. To our know-
ledge sCD163 has not been studied in PFAPA. Levels of
sCD163 were not changed during febrile episodes of
PFAPA and did not differ between children with PFAPA
and children with pneumonia. This may indicate that
there is not a pathological over-activation of macro-
phages in the PFAPA-syndrome.
Limitations
The diagnostic criteria for PFAPA made by Thomas et al.
have a high sensitivity for PFAPA, but do not exclude
other hereditary fever syndromes with an overlapping
clinical picture. The presence of mutations involved in
other genetic fevers has been found in Italian and Israeli
children fulfilling the PFAPA criteria [37,38], and a more
strict approach to diagnosing PFAPA has been proposed
[37]. However, hereditary periodic fever syndromes are
uncommon in the Scandinavian population [8], and in the
absence of additional characteristics we find it unlikely
that we have missed a diagnosis of a hereditary periodic
fever syndrome even without performing genetic testing.
We included a control group with pneumonia to study
any characteristics of PFAPA different from a common
bacterial infection. However, the value of such a control
group may be questioned due to the time difference of
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taken within the first 24 hours after the onset of a febrile
episode. For obvious reasons (they don’t see a doctor this
early), this was not possible in the children with pneumo-
nia. It is not unlikely that this time factor influences the
measurements and this must be considered when compar-
ing results of the two groups during febrile episodes.
The second sample in children with pneumonia was
taken after at least four weeks of complete remission. We
therefor consider this sample to be a good negative control,
and that the cytokine levels most likely reflect normal base
line values in these children.
Clinical studies of relatively uncommon disorders like
PFAPA usually have a long running-time in order to collect
a reasonable amount of samples. Although seldom de-
bated, this time-factor might influence the result as sam-
ples stored over a long period of time might deteriorate
[39]. We had to perform one thaw-freeze cycle before
sCD25 and sCD163 were analysed and it is possible that
this influenced the results of these analyses.
A large number of cytokines were analyzed, which
could implicate corrections for multiple comparisons.
However, some of the cytokines were randomly in-
cluded due to their inclusion in the multiplex kit and
not by indication. A full Bonferroni correction could
therefore be a very conservative approach with the pos-
sibility of false negative results (type II error). On the
other hand, in the absence of a correction for multiple
comparisons there is a risk of false positive result (type
I error). Being aware of this, we have interpreted our
data with caution and focused on the close resemblance
to previous studies. The relatively small sample size
should also be considered when interpreting the results
of this study.Conclusion
We have shown increased levels of cytokines during the
febrile attacks of PFAPA, indicating an innate immune re-
sponse as the initial step. Further, we found a decrease in
subsets of T cells, suggesting a subsequent adaptive im-
mune response with activation and redistribution of these
cells to local tissue. Levels of CXCL10 were increased in
PFAPA also during remission, suggesting a persistent acti-
vation of the innate immune system in these children.
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